JP2016536312A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536312A5
JP2016536312A5 JP2016527304A JP2016527304A JP2016536312A5 JP 2016536312 A5 JP2016536312 A5 JP 2016536312A5 JP 2016527304 A JP2016527304 A JP 2016527304A JP 2016527304 A JP2016527304 A JP 2016527304A JP 2016536312 A5 JP2016536312 A5 JP 2016536312A5
Authority
JP
Japan
Prior art keywords
composition
nanoparticle
cell
nanoparticle composition
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016527304A
Other languages
English (en)
Japanese (ja)
Other versions
JP6845691B2 (ja
JP2016536312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/063545 external-priority patent/WO2015066535A1/en
Publication of JP2016536312A publication Critical patent/JP2016536312A/ja
Publication of JP2016536312A5 publication Critical patent/JP2016536312A5/ja
Priority to JP2020028423A priority Critical patent/JP6929572B2/ja
Application granted granted Critical
Publication of JP6845691B2 publication Critical patent/JP6845691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016527304A 2013-11-01 2014-10-31 免疫療法のための調節粒子 Active JP6845691B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020028423A JP6929572B2 (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361899080P 2013-11-01 2013-11-01
US61/899,080 2013-11-01
US201462040242P 2014-08-21 2014-08-21
US62/040,242 2014-08-21
PCT/US2014/063545 WO2015066535A1 (en) 2013-11-01 2014-10-31 Modular particles for immunotherapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020028423A Division JP6929572B2 (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2020028424A Division JP2020075940A (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子

Publications (3)

Publication Number Publication Date
JP2016536312A JP2016536312A (ja) 2016-11-24
JP2016536312A5 true JP2016536312A5 (cg-RX-API-DMAC7.html) 2017-10-19
JP6845691B2 JP6845691B2 (ja) 2021-03-24

Family

ID=51999513

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016527304A Active JP6845691B2 (ja) 2013-11-01 2014-10-31 免疫療法のための調節粒子
JP2020028424A Withdrawn JP2020075940A (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2020028423A Active JP6929572B2 (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2022043714A Withdrawn JP2022078345A (ja) 2013-11-01 2022-03-18 免疫療法のための調節粒子

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020028424A Withdrawn JP2020075940A (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2020028423A Active JP6929572B2 (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2022043714A Withdrawn JP2022078345A (ja) 2013-11-01 2022-03-18 免疫療法のための調節粒子

Country Status (11)

Country Link
US (3) US9884026B2 (cg-RX-API-DMAC7.html)
EP (1) EP3062779B1 (cg-RX-API-DMAC7.html)
JP (4) JP6845691B2 (cg-RX-API-DMAC7.html)
KR (2) KR102460800B1 (cg-RX-API-DMAC7.html)
CN (2) CN110302162A (cg-RX-API-DMAC7.html)
AU (4) AU2014342004B2 (cg-RX-API-DMAC7.html)
CA (2) CA2987519A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982087T3 (cg-RX-API-DMAC7.html)
RU (1) RU2672055C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015066535A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602826B (cg-RX-API-DMAC7.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
EP2624873B1 (en) 2010-10-06 2019-12-04 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2836234B1 (en) 2012-04-12 2019-06-12 Yale University Vehicles for controlled delivery of different pharmaceutical agents
LT2838515T (lt) 2012-04-16 2020-03-10 President And Fellows Of Harvard College Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
AU2014248090B2 (en) 2013-04-03 2018-08-02 N-Fold Llc Novel nanoparticle compositions
KR102460800B1 (ko) 2013-11-01 2022-10-31 예일 유니버시티 면역요법용 모듈러 입자
EP3094314B1 (en) * 2014-01-16 2021-06-23 MUSC Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
WO2015148971A2 (en) 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
WO2015168379A2 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
WO2016149378A1 (en) 2015-03-16 2016-09-22 Pdx Pharmaceuticals, Llc Cross-linked polymer modified nanoparticles
CN107708756A (zh) 2015-04-10 2018-02-16 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
US10493030B2 (en) 2015-05-22 2019-12-03 Aphios Corporation Combination HIV therapeutic
AU2016267671B2 (en) * 2015-05-27 2021-09-23 Northwestern University Carbohydrate-modified particles and particulate formulations for modulating an immune response
CN120392779A (zh) * 2015-06-15 2025-08-01 华盛顿大学 用于延长血液和淋巴组织中的药物水平的多药脂质纳米颗粒组合物和相关方法
EP3331557B1 (en) 2015-08-04 2021-04-07 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
WO2017144543A1 (en) * 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and belinostat
JP6918816B2 (ja) * 2016-03-01 2021-08-18 ノース カロライナ ステート ユニバーシティ マイクロニードルパッチ支援送達による強化されたがん免疫療法
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
ES3032115T3 (en) 2016-07-13 2025-07-15 Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2018026884A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
WO2018057847A1 (en) 2016-09-23 2018-03-29 Duke University Unstructured non-repetitive polypeptides having lcst behavior
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
EP3595629A4 (en) * 2017-03-16 2021-01-06 Children's Medical Center Corporation NON-VIRAL, NON-CATIONIC NANOPARTICLES AND RELATED USES
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
GB201804634D0 (en) * 2018-03-22 2018-05-09 Aqdot Ltd Emulsion stabiliser
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
AU2019265632A1 (en) * 2018-05-09 2021-01-07 Yale University Particles for spatiotemporal release of agents
WO2020014270A1 (en) * 2018-07-10 2020-01-16 The Regents Of The University Of California Biomolecule coated particles and films and uses thereof
US20220072023A1 (en) * 2018-07-12 2022-03-10 The Regents Of The University Of Michigan Compositions and methods for metal containing formulations capable of modulating immune response
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US12180300B2 (en) 2018-09-20 2024-12-31 Arizona Board Of Regents On Behalf Of The University Of Arizona Targeting moiety-drug grafted immune cell compositions and methods of use
EP4635486A3 (en) * 2018-10-01 2025-12-24 The Board of Trustees of the Leland Stanford Junior University Injectable hydrogels for controlled release of immunomodulatory compounds
CA3115677A1 (en) * 2018-10-19 2020-04-23 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
RU2706427C1 (ru) * 2018-12-27 2019-11-19 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата
EP3911361A4 (en) * 2019-01-18 2022-10-12 University of Georgia Research Foundation, Inc. SALT NANOPARTICLES, AND COMPOSITIONS AND METHODS OF USE THEREOF
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
US12263252B2 (en) 2019-06-05 2025-04-01 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
WO2021011496A1 (en) * 2019-07-12 2021-01-21 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
US20220249389A1 (en) 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
US20220257516A1 (en) 2019-07-12 2022-08-18 Oregon Health & Science University Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US20220331415A1 (en) * 2019-09-18 2022-10-20 The Regents Of The University Of California Immunoactive microparticles and uses thereof
RU2712212C1 (ru) * 2019-10-28 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата
WO2021113638A1 (en) * 2019-12-05 2021-06-10 West Virginia University Protein-loaded plga nanospheres
WO2021137611A1 (ko) * 2019-12-30 2021-07-08 (주)테라베스트 나노 구조체가 부착된 면역세포
US20230093708A1 (en) * 2020-03-04 2023-03-23 Duke University Protein nanoparticle design and application
EP4149550A4 (en) * 2020-05-15 2024-07-03 The Board of Trustees of the Leland Stanford Junior University TOLL-LIKE RECEPTOR (TLR) AGONIST NANOPARTICLES AND USES THEREOF
EP4175618A4 (en) * 2020-07-01 2024-08-07 Cello Therapeutics, Inc. Platelet membrane coated nanoparticles and uses thereof
CN112451504B (zh) * 2020-11-09 2022-10-18 四川大学华西医院 一种载EBV-LMP2 mRNA的核-壳纳米粒的制备方法及应用
US11672875B2 (en) 2021-03-17 2023-06-13 Saint Louis University Nanoparticle-alginate gels for X-ray imaging of the vasculature
JP2024515107A (ja) * 2021-04-20 2024-04-04 パーデュー リサーチ ファウンデーション 抗腫瘍免疫療法としての免疫機能担体、使用方法及び組成物
GB2629999B (en) * 2021-04-21 2025-03-26 Act Therapeutics Ltd Enhancement of treatment with immunotherapeutic agents
WO2022225203A1 (ko) * 2021-04-23 2022-10-27 서울대학교산학협력단 대식세포의 활성 조절용 조성물
WO2023113545A1 (ko) * 2021-12-16 2023-06-22 주식회사 포투가바이오 αPD-1를 포함하는 수지상 세포 모방 기능성 나노구조체 및 이의 제조방법
WO2023113550A1 (ko) * 2021-12-16 2023-06-22 주식회사 포투가바이오 수지상세포 모방 기능성 나노구조체 및 이의 제조방법
WO2024128868A1 (ko) * 2022-12-15 2024-06-20 주식회사 포투가바이오 αPD-1를 포함하는 수지상 세포 모방 기능성 나노구조체 및 이의 제조방법
CN116172980A (zh) * 2022-12-28 2023-05-30 上海百心安生物技术股份有限公司 一种核壳结构胶束微球及其制备方法和应用
CN117731637A (zh) * 2023-12-20 2024-03-22 上海爱莫思生物技术有限公司 一种mdp纳米颗粒及其应用
WO2025149619A1 (en) * 2024-01-12 2025-07-17 Topas Therapeutics Gmbh Nanoparticles comprising amphiphilic polymers and lipids for the targeted delivery of antigens
CN120324344B (zh) * 2025-04-18 2025-10-17 广州医科大学附属第一医院横琴医院(横琴粤澳深度合作区中心医院) 一种肿瘤微环境响应型级联靶向小激活核酸纳米药物的制备方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
US5354867A (en) 1988-12-06 1994-10-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
WO1995015746A1 (en) 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7785578B2 (en) 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
CA2571899A1 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
NZ581779A (en) * 2005-05-17 2011-09-30 Univ Connecticut Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
MX349137B (es) 2005-06-08 2017-07-13 Dana-Farber Cancer Inst Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007005754A2 (en) 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
DE102005039579B4 (de) * 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US20070243184A1 (en) 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CN101341516A (zh) 2005-12-20 2009-01-07 皇家飞利浦电子股份有限公司 用于图像数据运动补偿的方法
JP2008053276A (ja) 2006-08-22 2008-03-06 Nec Electronics Corp 半導体装置の製造方法
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
JP2010524859A (ja) * 2007-04-13 2010-07-22 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワース 標的型癌ナノ治療に用いる、活性剤が負荷された活性化ｐｌｇａナノ粒子製剤
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
JPWO2009020094A1 (ja) 2007-08-09 2010-11-04 第一三共株式会社 疎水性分子で修飾した抗体
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
EP3936122A1 (en) * 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
WO2010083337A2 (en) 2009-01-15 2010-07-22 The Regents Of The University Of Califorinia Composite nanostructures and methods for making and using them
CN102048693B (zh) 2009-10-26 2013-08-21 石药集团中奇制药技术（石家庄）有限公司 具有苯磺酸衍生物内水相的脂质体
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
US20110293690A1 (en) 2010-05-27 2011-12-01 Tyco Healthcare Group Lp Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof
JP2013531043A (ja) 2010-07-16 2013-08-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 癌の免疫療法のための方法及び組成物
EP2640359A4 (en) 2010-11-18 2015-11-04 Gen Hospital Corp NOVEL COMPOSITIONS AND USES OF HYPOTENSE AGENTS IN THE TREATMENT OF CANCER
CN103635182A (zh) * 2011-05-09 2014-03-12 萨里亚化学研究院 用于药物递送的聚合物纳米颗粒
EP2836234B1 (en) 2012-04-12 2019-06-12 Yale University Vehicles for controlled delivery of different pharmaceutical agents
KR102460800B1 (ko) 2013-11-01 2022-10-31 예일 유니버시티 면역요법용 모듈러 입자

Similar Documents

Publication Publication Date Title
JP2016536312A5 (cg-RX-API-DMAC7.html)
RU2016121422A (ru) Модульные частицы для иммунотерапии
Phuengkham et al. A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy
Bauleth‐Ramos et al. Acetalated dextran nanoparticles loaded into an injectable alginate cryogel for combined chemotherapy and cancer vaccination
Ban et al. Emerging systemic delivery strategies of oncolytic viruses: a key step toward cancer immunotherapy
Fontana et al. Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?
Simpson et al. Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
Xu et al. Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12
Ramakrishnan et al. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer
Luo et al. Nanocarrier co-formulation for delivery of a TLR7 agonist plus an immunogenic cell death stimulus triggers effective pancreatic cancer chemo-immunotherapy
Zheng et al. Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer
Torres Andon et al. Nanomedicine and cancer immunotherapy–targeting immunosuppressive cells
WO2016018920A8 (en) Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
EP2620157A3 (en) Vaccine nanotechnology
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
García et al. Self-assembled nanomaterials
EP3064220A3 (en) Compositions and methods for the treatment of infections and tumors
JP2016513953A5 (cg-RX-API-DMAC7.html)
WO2015153805A3 (en) Targeted polymerized nanoparticles for cancer treatment
Lee et al. Poly d, l-lactide-co-glycolide (PLGA) nanoparticle-encapsulated honeybee (Apis melifera) venom promotes clearance of Salmonella enterica serovar Typhimurium infection in experimentally challenged pigs through the up-regulation of T helper type 1 specific immune responses
CN106237340B (zh) 透明质酸纳米颗粒在制备治疗淋巴系统肿瘤的药物的用途
Phung et al. Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review
Nikitczuk et al. PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival
JP2012506394A5 (cg-RX-API-DMAC7.html)